Literature DB >> 9267666

Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis.

T N Small1, D Avigan, B Dupont, K Smith, P Black, G Heller, T Polyak, R J O'Reilly.   

Abstract

Transplantation of T-cell depleted bone marrow has been associated with an increased risk of graft failure, requiring additional immunosuppression to prevent this complication. To determine the effect of graft rejection prophylaxis with posttransplant anti-thymocyte globulin and methylprednisolone on immune reconstitution, the lymphoid phenotype, function, and infectious complications of 170 recipients of a T-cell depleted bone marrow transplantation, 57 of whom received prophylaxis, were analyzed. Neutrophil recovery and normalization of T-cell numbers were more rapid in patients given anti-thymocyte globulin and methylprednisolone. Adults given graft rejection prophylaxis had prolonged inversion of their CD4/CD8 ratio, increased numbers of CD8+ CD11b+, HLA-DR+, CD57+, CD28- T cells, and delayed recovery of T-cell mitogen responses when compared to adults not given ATG and steroids. Even without posttransplant immunosuppression to prevent graft failure, adults experienced delayed recovery of total and CD45RA+ CD4+ cells, prolonged inversion of the CD4/CD8 ratio, and delayed recovery of T-cell mitogen responses when compared to children. During the first posttransplant year, Epstein-Barr Virus-Associated Lymphoproliferative disorders and opportunistic infections were increased in patients given prophylaxis. Patients who developed an opportunistic infection or EBV-LPD had significantly fewer circulating CD4+ T cells than those who did not. This study demonstrates that older age and graft rejection prophylaxis, rather than T-cell depletion alone, are associated with delayed immune reconstitution. In addition, it suggests that CD4 cell counts may be useful in predicting which patients are at increased risk of developing opportunistic infections following successful engraftment.

Entities:  

Mesh:

Year:  1997        PMID: 9267666

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  32 in total

Review 1.  Can studies of tolerance ever lead to therapy?

Authors:  H von Boehmer
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

2.  Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation.

Authors:  S Onder Alpdogan; Sydney X Lu; Neel Patel; Suzanne McGoldrick; David Suh; Tulin Budak-Alpdogan; Odette M Smith; Jeremy Grubin; Christopher King; Gabrielle L Goldberg; Vanessa M Hubbard; Adam A Kochman; Marcel R M van den Brink
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

Review 3.  Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation.

Authors:  Enrico Velardi; Jarrod A Dudakov; Marcel R M van den Brink
Journal:  Immunol Lett       Date:  2013-10-08       Impact factor: 3.685

Review 4.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Authors:  Jenna D Goldberg; Junting Zheng; Ravin Ratan; Trudy N Small; Kuan-Chi Lai; Farid Boulad; Hugo Castro-Malaspina; Sergio A Giralt; Ann A Jakubowski; Nancy A Kernan; Richard J O'Reilly; Esperanza B Papadopoulos; James W Young; Marcel R M van den Brink; Glenn Heller; Miguel-Angel Perales
Journal:  Leuk Lymphoma       Date:  2017-01-10

6.  Immune recovery after allogeneic hematopoietic stem cell transplantation: is it time to revisit how patients are monitored?

Authors:  Miguel-Angel Perales; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

7.  T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

Authors:  Ann A Jakubowski; Trudy N Small; Nancy A Kernan; Hugo Castro-Malaspina; Nancy Collins; Guenther Koehne; Katharine C Hsu; Miguel A Perales; Genovefa Papanicolaou; Marcel R M van den Brink; Richard J O'Reilly; James W Young; Esperanza B Papadopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

Review 8.  Novel strategies for adoptive therapy following HLA disparate transplants.

Authors:  Richard J O'Reilly; Aisha Hasan; Ekaterina Doubrovina; Guenther Koehne; Susan Prockop
Journal:  Best Pract Res Clin Haematol       Date:  2011-09       Impact factor: 3.020

9.  T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Authors:  Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos
Journal:  Blood       Date:  2007-08-23       Impact factor: 22.113

10.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Authors:  Hugo Castro-Malaspina; Ann A Jabubowski; Esperanza B Papadopoulos; Farid Boulad; James W Young; Nancy A Kernan; Miguel A Perales; Trudy N Small; Katharine Hsu; Michelle Chiu; Glenn Heller; Nancy H Collins; Suresh C Jhanwar; Marcel van den Brink; Stephen D Nimer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.